GSK-3 inhibition through GLP-1R allosteric activation mediates the neurogenesis promoting effect of P7C3 after cerebral ischemic/reperfusional injury in mice
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
&NA; An aminopropyl carbazole compound, P7C3, has been shown to be a potent neurogenesis promoting agent; however, its fundamental signaling action has yet to be elucidated. A cerebral ischemic/reperfusional (CI/R) injury model in mice was implemented to elucidate the neuronal protective mechanism(s) of P7C3. Treating CI/R mice using P7C3 (50–100 &mgr;g/kg, i.v.) significantly improved tracking distance and walking behavior, and reduced brain damage. Specifically, P7C3 promoted the expression of neurogenesis‐associated proteins, including doublecortin, beta tubulin III (&bgr;‐tub3), adam11 and adamts20, near the peri‐infarct cortex, accompanied by glycogen synthase kinase 3 (GSK‐3) inhibition and &bgr;‐catenin upregulation. The application of a specific inhibitor against glucagon‐like peptide 1 receptor (GLP‐1R), exendin(9‐39), revealed that the beneficial effects of P7C3 involved triggering the activation of GLP‐1R‐associated PKA/Akt signaling. P7C3 elicited the GLP‐1R‐dependent intracellular cAMP increment and the insulin secretion in cellular models. Surface plasmon resonance assay of P7C3 showed a Kd value of 0.53 &mgr;M for GLP‐1R binding, and the docking of P7C3 to the putative active site on GLP‐1R was successfully predicted by molecular modeling. Our findings indicate that P7C3 promotes the expression of neurogenesis proteins by activation of the cAMP/PKA‐dependent and Akt/GSK3‐associated &bgr;‐catenin through positive allosteric stimulation of GLP‐1R. Within the P7C3 class of neuroprotective molecules, this mechanism appears to be unique to the prototypical P7C3 molecule, as other active derivatives such as P7C2‐A20 and P7C3‐S243 they do not engage this same pathway and have been shown to work by nicotinamide phosphoribosyltransferase (NAMPT) stimulation. Graphical abstract Figure. No caption available. HighlightsP7C3 promoted neurogenesis in stroke mice with GSK‐3 inhibition/&bgr;‐catenin upregulation.Using GLP‐1R antagonist revealed P7C3 triggered PKA/Akt/GSK3‐dependent &bgr;‐catenin signaling.P7C3 showed a specific binding activity for GLP‐1R with a Kd value of 0.53 &mgr;M by SPR assay.Molecular modeling successfully predicted P7C3 can dock into the putative active site on GLP‐1R.P7C3 promoted neurogenesis in ischemic stroke mice by positive allosteric stimulation of GLP‐1R.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Science of Stroke: Mechanisms in Search of Treatments
Moskowitz, M. A., Lo, E. H., & Iadecola, C. (2010) · Neuron · doi:10.1016/j.neuron.2010.07.002 · Cited by 1,930
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345
P7C3 Neuroprotective Chemicals Function by Activating the Rate-Limiting Enzyme in NAD Salvage
Wang, G., Han, T., Nijhawan, D., Theodoropoulos, P., Naidoo, J., Yadavalli, S., Mirzaei, H., Pieper, A. A., Ready, J. M., & McKnight, S. L. (2014) · Cell · doi:10.1016/j.cell.2014.07.040 · Cited by 243
Walker, A. K., Rivera, P. D., Wang, Q., Chuang, J.-C., Tran, S., Osborne-Lawrence, S., Estill, S. J., Starwalt, R., Huntington, P., Morlock, L., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.34 · Cited by 161
Meng, J., Ma, X., Wang, N., Jia, M., Bi, L., Wang, Y., Li, M., Zhang, H., Xue, X., Hou, Z., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.02.002 · Cited by 155
Self-citationNeuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis
Tesla, R., Wolf, H. P., Xu, P., Drawbridge, J., Estill, S. J., Huntington, P., McDaniel, L., Knobbe, W., Burket, A., Tran, S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213960109 · Cited by 129
Voorhees, J. R., Remy, M. T., Cintrón-Pérez, C. J., El Rassi, E., Khan, M. Z., Dutca, L. M., Yin, T. C., McDaniel, L. N., Williams, N. S., Brat, D. J., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.023 · Cited by 78
Cited by
Kim, Y.-K., Kim, O. Y., & Song, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01270 · Cited by 109
“Further, the expression of neurogenesis-related proteins was promoted by the activation of the cAMP/PKA and Akt/ GSK3 signaling pathways through the stimulation of GLP-1R in mice (Wang et al., 2018).”
BackgroundLi, J., Ma, S., Chen, J., Hu, K., Li, Y., Zhang, Z., Su, Z., Woodgett, J. R., Li, M., & Huang, Q. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00081 · Cited by 76
Yang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
Maskery, M. P., Holscher, C., Jones, S. P., Price, C. I., Strain, W. D., Watkins, C. L., Werring, D. J., & Emsley, H. C. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20952011 · Cited by 51
“proliferation markers (ki67, BrdU) and neurodevelopmental markers (adam11, adamts20) alongside markers of increased neurogenesis (GSK-3 inhibition).(49) Darsalia et al.”
Background
Metadata
- Authors
- Wang, Y.-H., Liou, K.-T., Tsai, K.-C., Liu, H.-K., Yang, L.-M., Chern, C.-M., & Shen, Y.-C.
- Venue
- Toxicology and Applied Pharmacology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 357
- Pages
- 88-105
- ISSN
- 0041-008X (ISSN-L)
- OpenAlex
- W2890215758
- Cited by
- 22
- References
- 8
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.